U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
U.S. health officials finalized guidelines for infant formula makers that aim to ensure products meet certain quality controls to keep them safe.
Some of Wednesday's midday movers:
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
The FTC has sued pharmaceutical companies $1 billion for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired.
A couple of stocks stand to gain over the next two weeks, Paul Hickey of Bespoke Investment Group says.
Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?
In his book "Get Rich Carefully," CNBC's "Mad Money" host explains how spotting long-term megatrends can help investors surf the wave of profitability.
Cramer believes there’s always opportunity in the market. You simply have to know where to look.
Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.
Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.
Jim Cramer has been a fan of this company for quite some time. But a good stock always needs new catalysts.
Investing is a bit like an Ellery Queen mystery. If you can follow the clues you should find what you're seeking - upside.
More large American corporations are reducing their tax bill by buying a foreign company and effectively renouncing their United States citizenship.
The Mad Money host always suggests watching for dips. But is the weakness in Perrigo really a buying opportunity?
Uncertainty about the Fed is making stocks nervous and is adding to a growing bearishness about the market.
A new development suggests big companies may be getting fed up with Washington. Really fed up.
Sick of high U.S. corporate taxes? Here's how some companies are slashing their tax bill by 10%, 20%—or more.
Who’s best for the markets, Yellen or Summers? Wall Street debates while awaiting Obama’s pick for the next Fed chairman.
Cramer says a trio of recent deals demands attention.